US Stock Market Closed

Dashboard

Fate Therapeutics, Inc. (FATE)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

CEO

J. Scott Wolchko

Employees

178

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

San Diego

Exchange

NASDAQ

Summary Stats

Market Cap

2.47B

Revenue

63.1M

Net Income

-233M

EPS

-$2.44

Price-to-Earnings

-10.5

Price-to-Book

3.91

Debt-to-Equity

0.36

News

Analyst Ratings

Price targets projected by 14 analysts

High

$71.00

Average

$54.36

Low

$30.00

Ratings calculated by 14 analysts

Buy

12

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.08

Actual

-$0.68 +10.5%

Consensus

-0.76

Report Date

Year Ago

-0.48

Year Ago Change %

Down 41%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites